micro-community-banner
 
  • Saved
Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells - PubMed

Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34919342/

Regulatory T cells (Tregs) play an important role in controlling autoimmunity and limiting tissue damage and inflammation. IL2-inducible T cell kinase (Itk) is part of the Tec family of tyrosine...


Conclusion: This peptide inhibitor also significantly reduced inflammatory cytokine production in primary GVHD patient samples and mouse T cells without causing cell death or apoptosis. We provide evidence that specifically targeting Itk signaling could be a therapeutic strategy to treat autoimmune disorders.

  • Saved
Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients - PubMed

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34880598/

1 Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, People's Republic of China. 2 Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,...


Conclusion: Our real-world data from Chinese patients further confirm that ruxolitinib is a safe and effective treatment for SR-GVHD.

  • Saved
Updates in chronic graft-versus-host disease - PubMed

Updates in chronic graft-versus-host disease - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34889364/

Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations of chronic GVHD are heterogeneous and pleomorphic, and there...


Conclusion/Relevance: Multi-institutional collaboration and pharmaceutical support in the development of therapies based on sound biologic mechanisms and clinical trials with defined end points and responses have led to several promising agents on the horizon of approval for treatment of chronic GVHD. This article reviews advances in our...

  • Saved
Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I | Pathologica - Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology

Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I | Pathologica - Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology

Source : https://www.pathologica.it/article/view/337

The neonatal and paediatric spectrum of small bowel disorders encompass a wide variety of conditions, ranging from food allergies to life-threatening surgical emergencies or lifelong medical conditions and, as such,...


Conclusion/Relevance: Specifically, in this first part, we describe congenital and metabolic disorders, intestinal lymphangiectasia, immunodeficiencies, GVHD, and necrotising enterocolitis.

  • Saved
Mesenchymal Stem Cells Enhance Chemotaxis of Activated T Cells through the CCL2-CCR2 Axis In Vitro - Bulletin of Experimental Biology and Medicine

Mesenchymal Stem Cells Enhance Chemotaxis of Activated T Cells through the CCL2-CCR2 Axis In Vitro - Bulletin of Experimental Biology and Medicine

Source : https://link.springer.com/article/10.1007/s10517-021-05373-3

Activation and migration of donor T cells to the host target organs are critical mechanisms in the pathogenesis of graft-versus-host disease (GVHD). The role of monocyte chemoattractant protein-1 (MCP-1/CCL2) and...


Conclusion/Relevance: Our results show that CCL2 levels in supernatants of co-cultures were significantly higher than in MSC monoculture and this increase depended on the number of MSC. MSC inhibited proliferation of T cells, but did not change the percentages of CD4 and CD8 T cells subsets. MSC can up-regulate the CCR2 expression in CD8 ...